# Efinopegdutide for MASH with liver fibrosis: phase 2b trial

Source: https://pepvault.app/research/efinopegdutide-lawitz-2026

Last updated: 2026-11-18

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Research](https://pepvault.app/research) [Efinopegdutide](https://pepvault.app/research#efinopegdutide)

Randomized trial · people

# Efinopegdutide: MASH resolved in up to 63% vs 13% on placebo

Checked against the paper November 2026 Randomized trial [Published by PepVault](https://pepvault.app/guides/how-we-research)

## The takeaway

In adults with MASH and stage 2-3 scarring, efinopegdutide cleared MASH in far more people than placebo over a year, and side effects were most common at 10 mg.

- **Kind:** Randomized trial
- **Studied in:** People
- **Number studied:** 381
- **Published:** 2026
- **Journal:** Lancet

## What they tested

The team tested whether weekly efinopegdutide could clear MASH and reduce liver scarring in adults without cirrhosis, compared with placebo.

## How the study was done

A phase 2b, randomized, double-blind, placebo-controlled trial at 176 centers in 26 countries. Of 386 adults randomized, 381 received at least one dose. All had biopsy-confirmed MASH (fatty liver with inflammation) and stage 2 or stage 3 fibrosis (scarring). They got weekly shots of efinopegdutide 4 mg, 7 mg or 10 mg, placebo (a dummy shot), or open-label semaglutide 2.4 mg for 52 weeks.

<!--promo-->

PepVault for iPhone

## Taking efinopegdutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## What they found

At week 52, MASH went away without fibrosis getting worse in 31 of 55 people (56%) in the 4 mg arm, 31 of 49 (63%) in the 7 mg arm and 35 of 57 (61%) in the 10 mg arm, compared with 7 of 53 (13%) on placebo. Gaps versus placebo were 43.0, 49.5 and 47.8 percentage points, all p<0.0001. On semaglutide, 26 of 49 (53%) met this goal. Fibrosis improved by at least one stage without worse inflammation in 43% (4 mg), 52% (7 mg) and 34% (10 mg) versus 21% on placebo. The 10 mg result did not reach statistical significance (p=0.072). Gut side effects were the most common, and they were highest at 10 mg. At 10 mg, 11% stopped treatment due to side effects, versus 3-4% at the lower doses and 1% on placebo.

## What it doesn’t show

This was a mid-stage trial that lasted 1 year. It does not show longer-term liver outcomes. The semaglutide arm was open-label, and the trial was funded by Merck Sharp & Dohme.

## The paper

Lawitz et al. Efficacy and safety of efinopegdutide in adults with metabolic dysfunction-associated steatohepatitis and stage 2-3 fibrosis: a phase 2b, randomised, placebo-controlled study. Lancet. 2026.

- [PubMed (PMID 43003105)](https://pubmed.ncbi.nlm.nih.gov/43003105/)
- [The paper (DOI 10.1016/S0140-6736(26)02043-X)](https://doi.org/10.1016/S0140-6736%2826%2902043-X)
- [ClinicalTrials.gov (NCT05877547)](https://clinicaltrials.gov/study/NCT05877547)

## The compound

- [Efinopegdutide: how it works, half-life, studied range and evidence](https://pepvault.app/peptides/efinopegdutide)
- [Efinopegdutide dose guide](https://pepvault.app/lab/dosage/efinopegdutide)

## With this study

### Efinopegdutide

- [Efinopegdutide: the full reference](https://pepvault.app/peptides/efinopegdutide)
- [Efinopegdutide dose guide](https://pepvault.app/lab/dosage/efinopegdutide)

### Mixing charts

- [10 mg vial](https://pepvault.app/tools/reconstitution-calculator/efinopegdutide-10mg)

### Studies

- [Efinopegdutide: 72.7% liver fat drop vs 42.3% on semaglutide](https://pepvault.app/research/efinopegdutide-romero-gomez-2023)
- [Efinopegdutide: up to 7.2% more weight loss than placebo at 12 weeks](https://pepvault.app/research/efinopegdutide-di-prospero-2021)
- [All 3 studies](https://pepvault.app/research#efinopegdutide)

### Compared with

- [Semaglutide vs Efinopegdutide](https://pepvault.app/peptides/compare/semaglutide-vs-efinopegdutide)
- [Survodutide vs Efinopegdutide](https://pepvault.app/peptides/compare/survodutide-vs-efinopegdutide)
- [Pemvidutide vs Efinopegdutide](https://pepvault.app/peptides/compare/pemvidutide-vs-efinopegdutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### Terms on this page

- [Placebo](https://pepvault.app/glossary/placebo)
- [Double-blind](https://pepvault.app/glossary/double-blind)
- [Open-label](https://pepvault.app/glossary/open-label)
- [MASH](https://pepvault.app/glossary/mash)

## More studies on Efinopegdutide

- [Efinopegdutide: 72.7% liver fat drop vs 42.3% on semaglutide](https://pepvault.app/research/efinopegdutide-romero-gomez-2023) Randomized trial · people · 2023
- [Efinopegdutide: up to 7.2% more weight loss than placebo at 12 weeks](https://pepvault.app/research/efinopegdutide-di-prospero-2021) Randomized trial · people · 2021
- [Every study on Efinopegdutide](https://pepvault.app/research#efinopegdutide)

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed November 2026. Spot an error? [feedback@pepvault.app](mailto:feedback@pepvault.app). [How we research](https://pepvault.app/guides/how-we-research). This page reports one study; it is not medical advice.

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-next&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking efinopegdutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking efinopegdutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this study

### Efinopegdutide

- [Efinopegdutide: the full reference](https://pepvault.app/peptides/efinopegdutide)
- [Efinopegdutide dose guide](https://pepvault.app/lab/dosage/efinopegdutide)

### Mixing charts

- [10 mg vial](https://pepvault.app/tools/reconstitution-calculator/efinopegdutide-10mg)

### Studies

- [Efinopegdutide: 72.7% liver fat drop vs 42.3% on semaglutide](https://pepvault.app/research/efinopegdutide-romero-gomez-2023)
- [Efinopegdutide: up to 7.2% more weight loss than placebo at 12 weeks](https://pepvault.app/research/efinopegdutide-di-prospero-2021)
- [All 3 studies](https://pepvault.app/research#efinopegdutide)

### Compared with

- [Semaglutide vs Efinopegdutide](https://pepvault.app/peptides/compare/semaglutide-vs-efinopegdutide)
- [Survodutide vs Efinopegdutide](https://pepvault.app/peptides/compare/survodutide-vs-efinopegdutide)
- [Pemvidutide vs Efinopegdutide](https://pepvault.app/peptides/compare/pemvidutide-vs-efinopegdutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### Terms on this page

- [Placebo](https://pepvault.app/glossary/placebo)
- [Double-blind](https://pepvault.app/glossary/double-blind)
- [Open-label](https://pepvault.app/glossary/open-label)
- [MASH](https://pepvault.app/glossary/mash)

<!--promo-->

PepVault for iPhone

## Taking efinopegdutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## Research

- [All studies](https://pepvault.app/research)
- [Every study on Efinopegdutide](https://pepvault.app/research#efinopegdutide)

## The library

- [Efinopegdutide](https://pepvault.app/peptides/efinopegdutide)
- [Efinopegdutide dose guide](https://pepvault.app/lab/dosage/efinopegdutide)
- [The peptide reference library](https://pepvault.app/peptides)

## How we work

- [How we research](https://pepvault.app/guides/how-we-research)
- [How we check the library](https://pepvault.app/about#library)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
